- Home
- SAVA vs SILC Comparison
SAVA vs SILC Comparison
Compare SAVA & SILC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- SILC
- Stock Information
- Founded
- SAVA 1998
- SILC 1987
- Country
- SAVA United States
- SILC Israel
- Employees
- SAVA N/A
- SILC N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- SILC Computer Manufacturing
- Sector
- SAVA Health Care
- SILC Technology
- Exchange
- SAVA Nasdaq
- SILC Nasdaq
- Market Cap
- SAVA 102.4M
- SILC 86.2M
- IPO Year
- SAVA N/A
- SILC 1994
- Fundamental
- Price
- SAVA $2.11
- SILC $18.30
- Analyst Decision
- SAVA Hold
- SILC Hold
- Analyst Count
- SAVA 1
- SILC 1
- Target Price
- SAVA $2.00
- SILC N/A
- AVG Volume (30 Days)
- SAVA 517.9K
- SILC 11.6K
- Earning Date
- SAVA 11-06-2025
- SILC 10-30-2025
- Dividend Yield
- SAVA N/A
- SILC N/A
- EPS Growth
- SAVA N/A
- SILC N/A
- EPS
- SAVA N/A
- SILC N/A
- Revenue
- SAVA N/A
- SILC $58,651,000.00
- Revenue This Year
- SAVA N/A
- SILC $6.53
- Revenue Next Year
- SAVA N/A
- SILC $14.10
- P/E Ratio
- SAVA N/A
- SILC N/A
- Revenue Growth
- SAVA N/A
- SILC N/A
- 52 Week Low
- SAVA $1.15
- SILC $12.29
- 52 Week High
- SAVA $33.98
- SILC $19.37
- Technical
- Relative Strength Index (RSI)
- SAVA 44.15
- SILC 69.65
- Support Level
- SAVA $2.12
- SILC $17.15
- Resistance Level
- SAVA $2.19
- SILC $19.36
- Average True Range (ATR)
- SAVA 0.10
- SILC 0.68
- MACD
- SAVA -0.02
- SILC 0.23
- Stochastic Oscillator
- SAVA 6.45
- SILC 73.23
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.